PROVID-19: Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress

Sponsor
Centre Hospitalier Régional d'Orléans (Other)
Overall Status
Recruiting
CT.gov ID
NCT04363463
Collaborator
(none)
268
19
2
24
14.1
0.6

Study Details

Study Description

Brief Summary

The SARS-Cov2 viral pandemic is responsible for a new infectious disease called COVID-19 (CoronaVIrus Disease), is a major health problem. Respiratory complications occur in 15 to 40%, the most serious is acute respiratory distress syndrome (ARDS).

The management of COVID-19 is essentially symptomatic with respiratory oxygen supplementation in mild forms to invasive mechanical ventilation in the most severe forms.

Prone position (PP) reduced mortality in patients with ARDS in intensive care. Ding et al showed that PP and high flow oxygenation reduced the intubation in patients with moderate to severe ARDS.

The investigators hypothesize that the use of PP in spontaneously ventilation patients under oxygen standard could decrease incidence of intubation or non-invasive ventilation or death compared to conventional positioning management in medical departments.

Condition or Disease Intervention/Treatment Phase
  • Other: prone position
N/A

Detailed Description

This is a multicenter randomized controlled study. 400 patients with COVID-19 documentation and undergoing oxygen therapy will be randomly assigned, with a 1:1 ratio, to conventional positioning or repeated prone sessions.

The control group will have conventional positioning: semi-seated in bed or seated in a chair. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).

The intervention group will have:
  • Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.

  • The maximum of prone position at night. Patients must be able to take position by themselves or with minimal assistance. The rails will be positioned in order to prevent falling out of bed. The patient will be free to choose his preferred prone position as long as the back is not compressed

Study Design

Study Type:
Interventional
Anticipated Enrollment :
268 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized controlled multicenter trial Ratio 1:1Randomized controlled multicenter trial Ratio 1:1
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress
Actual Study Start Date :
Aug 28, 2020
Anticipated Primary Completion Date :
Aug 28, 2022
Anticipated Study Completion Date :
Aug 28, 2022

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Conventional positioning

semi-seated in bed or seated in a chair during the day. The prone position is not allowed during the day (it is allowed at night if it is the natural sleeping position).

Experimental: Interventional positioning : prone position

Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.

Other: prone position
Two sessions minimum of prone position over the day. With a total objective of at least 2h30 of cumulated duration over the day. The objective is to spend as much time as possible in prone position if the patient tolerates it well.

Outcome Measures

Primary Outcome Measures

  1. Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups. [Day 28]

    To show that PP in spontaneously ventilation patients could reduce the risk of acquiring the following event (composite endpoint): Endotracheal intubation Or non-invasive ventilation (NIV) with two pressure levels And/or death

Secondary Outcome Measures

  1. Duration in days for the change of 2 points on the WHO ordinal scale [Day 28]

    Show that the use of prone position improves the WHO ordinal scale score by 2 points faster (after randomization)

  2. Rate (%) of intubation and invasive ventilation in the 2 randomization groups. [Day 28]

    Show that prone position with spontaneous ventilation reduces the need for endotracheal intubation and invasive mechanical ventilation

  3. Rate (%) of non-invasive ventilation at two pressure levels in the 2 randomization groups [Day 28]

    Show that prone position with spontaneous ventilation reduces the use of non-invasive ventilation at two pressure levels

  4. Duration of oxygen therapy in the 2 randomization groups. [Day 28]

    Show that prone position in spontaneous ventilation reduces the time under oxygen therapy.

  5. Duration of hospitalization in the 2 randomization groups. [Day 28]

    Show that prone position reduces the length of hospitalization.

  6. Hospital mortality and mortality at D28 in the 2 randomization groups [Day 28]

    Compare the hospital mortality of the 2 groups

  7. Rate (%) of need for transfer to intensive care unit [Day 28]

    Compare the incidence of the need for resuscitation transfer between the two groups.

  8. Rate (%) of use of non-invasive ventilation at two pressure levels, intubation throughout the entire stay when the stay is longer than 28 days. [1 year]

    Compare the impact of the use of non-invasive ventilation and intubation on the entire hospital stay when the hospital stay is longer than 28 days between the two groups.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients aged from 18 to 85 years old

  • With COVID-19 documentation

  • Undergoing oxygen therapy (nasal cannula, medium or high concentration mask or high flow nasal oxygen therapy)

  • Able to move to PP by him/herself or with minimal assistance

  • Written consent

  • Hospitalized in COVID medical department for less than 72 hours

Exclusion Criteria:
  • Pregnant (positive pregnancy test during screening) or breastfeeding women

  • Patient on long-term oxygen therapy or Continuous Positive Airway Pressure (CPAP) or Non-Invasive Ventilation (NIV) at home

  • Chronic Obstructive Pulmonary Disease (COPD) Patient stage 3 or 4

  • Patient with known chronic diffuse interstitial lung disease

  • Patient with neuromuscular pathology

  • Contraindication to the PP (recent thoracic trauma, pneumothorax, orthopaedic fracture preventing mobilization, ...)

  • Deep vein thrombosis of the lower limbs or pulmonary embolism with effective anticoagulation for less than 48 hours

  • Hemodynamic instability (MAP < 65 mm Hg) persisting for more than 1 hour

  • Respiratory rate greater than 40 cycles per minute

  • Excessive use of accessory respiratory muscles (as judged by the clinician)

  • Indication for curative NIV (acute pulmonary edema or acute hypercapnic respiratory failure)

  • Intestinal Occlusive Syndrome

  • Patient unable to protect upper airway

  • Inability to understand French or to follow instructions for the prone position.

  • Person under guardianship

  • Protected Majors

  • Not affiliated to French social security

  • Decision not to forgo life sustaining therapy

  • Patient discharged from an intensive care unit and has been treated by invasive or non-invasive mechanical ventilation at 2 pressure levels during the resuscitation stay.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CH de Blois Blois France 41016
2 CH de DAX Dax France 40100
3 CHD de VENDEE La Roche sur Yon France 85925
4 CH de LA ROCHELLE La Rochelle France 17019
5 CH Le Mans Le Mans France 72037
6 CH Mont de MArsan Mont-de-Marsan France 40012
7 CHR d'Orléans - Service Pneumologie Orléans France 45000
8 CHR d'Orleans - Service Maladies Infectieuses Orléans France 45067
9 HOPITAL LARIBOISIERE - Service diabétologie, endocrinologie, nutrition Paris France 75010
10 Hopital Européen Georges Pompidou Paris France
11 Hopital Lariboisiere - Medecine Interne Paris France
12 Hopital Lariboisiere Paris France
13 CH de PERPIGNAN - Service Maladies infectieuses Perpignan France 66046
14 Centre Hospitalier Intercommunal de Cornouaille - Quimper Concarneau Quimper France 29000
15 CHRU de Tours - Service Médecine interne et immunologie Clinique Tours France 37000
16 CHRU de Tours - Service Pneumologie Tours France 37000
17 CHRU DE TOURS - Service Médecine interne et maladies infectieuses Tours France 37044
18 CH Bretagne Atlantique Vannes France 56017
19 centre Hospitalier Princesse Grace Monaco Monaco

Sponsors and Collaborators

  • Centre Hospitalier Régional d'Orléans

Investigators

  • Study Chair: Mai-Anh NAY, Dr, CHR Orléans

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Centre Hospitalier Régional d'Orléans
ClinicalTrials.gov Identifier:
NCT04363463
Other Study ID Numbers:
  • CHRO-2020-09
First Posted:
Apr 27, 2020
Last Update Posted:
Dec 2, 2021
Last Verified:
Dec 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Régional d'Orléans
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 2, 2021